YC W22 · Acquired

Engage Bio

Potent, durable, and redosable non-viral genetic medicines

Class: Winter 2022
Status: Acquired
Industry: Healthcare
Location: San Francisco, CA, USA
Team size: 10

Website

About

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.